BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vemurafenib: Phase Ib started

Roche began an open-label, dose-escalation, international Phase Ib trial to evaluate oral vemurafenib plus oral GDC-0973 in about 50 patients. Vemurafenib is in Phase III testing for the indication. Roche has exclusive, worldwide rights...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >